Cybin Inc. announced the appointment of Michael Halstead as Chief Executive Officer, effective August 3, 2026. Halstead previously served as President of Intra-Cellular Therapies, where he led the company's US$14.6 billion acquisition by Johnson & Johnson in 2025 and managed its commercialization efforts. His appointment coincides with Helus Pharma preparing for topline data readout from the APPROACH Phase 3 study of HLP003 for Major Depressive Disorder, expected in Q4 2026. The company continues enrollment in the EMBRACE Phase 3 study and the EXTEND long-term extension trial. Cybin Inc. operates as a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.
